Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182840 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 714
- Enrollment target
NCT05182840 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 714 participants.
The verdict
NCT05182840, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 714 participants
- Enrollment target
Study Summary
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Empagliflozin
- DRUG BI 690517
- DRUG Placebo to BI 690517
- DRUG Placebo to empagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2022-01-11 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182840
The ClinicalTrials.gov registry entry for NCT05182840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Empagliflozin is the first listed.
NCT05182840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05182840 about?
NCT05182840 is a clinical study titled "A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease". This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combinati...
What is the current status of trial NCT05182840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 714 participants. The study started on 2022-01-11. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT05182840?
The interventions under investigation include: Empagliflozin (DRUG), BI 690517 (DRUG), Placebo to BI 690517 (DRUG), Placebo to empagliflozin (DRUG).
Who is sponsoring clinical trial NCT05182840?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.